Russell Investments Group Ltd. trimmed its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 5.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 403,382 shares of the biopharmaceutical company’s stock after selling 22,234 shares during the period. Russell Investments Group Ltd. owned 0.20% of Incyte worth $49,044,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of INCY. Fifth Third Bancorp raised its stake in shares of Incyte by 7.6% in the third quarter. Fifth Third Bancorp now owns 29,647 shares of the biopharmaceutical company’s stock worth $3,598,000 after buying an additional 2,090 shares during the period. Maryland State Retirement & Pension System lifted its position in shares of Incyte by 12.4% during the 3rd quarter. Maryland State Retirement & Pension System now owns 9,790 shares of the biopharmaceutical company’s stock valued at $1,188,000 after buying an additional 1,081 shares in the last quarter. Ritholtz Wealth Management lifted its position in shares of Incyte by 97.5% during the 3rd quarter. Ritholtz Wealth Management now owns 19,195 shares of the biopharmaceutical company’s stock valued at $2,329,000 after buying an additional 9,475 shares in the last quarter. Lido Advisors LLC grew its stake in shares of Incyte by 1.2% during the 3rd quarter. Lido Advisors LLC now owns 18,556 shares of the biopharmaceutical company’s stock valued at $2,252,000 after acquiring an additional 229 shares during the period. Finally, Keybank National Association OH grew its stake in shares of Incyte by 6.9% during the 3rd quarter. Keybank National Association OH now owns 2,626 shares of the biopharmaceutical company’s stock valued at $319,000 after acquiring an additional 169 shares during the period. 96.97% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on INCY. UBS Group set a $152.00 target price on shares of Incyte in a report on Friday, October 30th. Sanford C. Bernstein raised their target price on shares of Incyte from $104.00 to $108.00 and gave the stock a “market perform” rating in a research note on Monday, November 2nd. Guggenheim lifted their price target on shares of Incyte from $136.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Weiss Ratings lowered shares of Incyte from a “buy (b)” rating to a “hold (c)” rating in a research report on Wednesday, November 4th. Finally, Zacks Research upgraded shares of Incyte from a “strong sell” rating to a “hold” rating in a research report on Thursday. Eleven research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $132.86.
View Our Latest Report on Incyte
Incyte Price Performance
NASDAQ:INCY opened at $120.97 on Monday. The business’s 50-day simple moving average is $119.18 and its two-hundred day simple moving average is $108.96. The stock has a market cap of $24.66 billion, a PE ratio of 64.35, a P/E/G ratio of 4.40 and a beta of 0.78. Incyte Corporation has a 52 week low of $89.25 and a 52 week high of $132.60.
Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, beating the consensus estimate of ($3.93) by $0.33. The business had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The business’s revenue was up 14.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.26 earnings per share. Sell-side analysts anticipate that Incyte Corporation will post 2.24 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider Thomas Tray sold 610 shares of Incyte stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total transaction of $72,565.60. Following the sale, the insider owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. This trade represents a 2.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Steven Stein sold 240,193 shares of Incyte stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $118.39, for a total value of $28,436,449.27. Following the sale, the chief marketing officer directly owned 30,916 shares in the company, valued at $3,660,145.24. This trade represents a 88.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 254,246 shares of company stock worth $30,162,968. 16.20% of the stock is owned by corporate insiders.
About Incyte
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
Recommended Stories
- Five stocks we like better than Incyte
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
